Trial Profile

A pivotal phase III trial assessing ECT-001 in patients with high-risk leukemia and myelodysplastic-syndromes

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 29 Mar 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dorocubicel (Primary)
Indications Leukaemia; Myelodysplastic syndromes
Focus Registrational; Therapeutic Use
Sponsors ExCellThera

Most Recent Events

29 Mar 2019 New trial record
25 Mar 2019 According to a ExCellThera Inc. media release, this study will be conducted at the Fred Hutchinson Cancer Centre in Seattle, Washington. The company plans to commence this trial in the coming months.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com